Abstract
Retrocyclins are synthetic θdefensins that were reconstructed from genetic blueprints that had remained unused for at least 7.5 million years. From phylogenetic studies, it appears that θdefensins arose in Old World Monkeys, after that lineage had separated from the prosimians and New World Monkeys. Although some nonhuman primates continue to produce θdefensin peptides today, Homo sapiens and his gorilla, bonobo, and chimpanzee relatives do not. Their inability to do so reflects the common inheritance of defective θdefensin genes which contain a premature stop codon that aborts translation. We can only speculate if this ancient genetic event has any contemporary relevance. However, it is noteworthy that synthetic retrocyclins can prevent the entry of HIV-1 and other viruses (e.g., HSV-2) into otherwise susceptible human target cells. Our studies suggest that their antiviral properties are intimately linked to an ability to bind carbohydrate epitopes displayed by viral and cell-surface glycoproteins involved in viral entry. The ability of retrocyclins to recognize and bind carbohydrate and glycan moieties is shared by θdefensins (RTDs) from rhesus monkeys and by several - but not all - human αdefensins. In addition to being the only cyclic peptides of animal origin, the lectin-like activity of θdefensins gives them the added distinction of being the smallest sugar-binding molecules of natural origin identified to date. This unusual combination makes θdefensins intriguing molecular prototypes that could be used to design novel carbohydrate-binding or antiviral agents.
Keywords: antiviral, cyclic peptides, hiv-1 uptake inhibitors, lectin, retrocyclin, theta-defensin
Current Protein & Peptide Science
Title: Retrocyclins: Using Past as Prologue
Volume: 5 Issue: 5
Author(s): Alexander M. Cole, Wei Wang, Alan J. Waring and Robert I. Lehrer
Affiliation:
Keywords: antiviral, cyclic peptides, hiv-1 uptake inhibitors, lectin, retrocyclin, theta-defensin
Abstract: Retrocyclins are synthetic θdefensins that were reconstructed from genetic blueprints that had remained unused for at least 7.5 million years. From phylogenetic studies, it appears that θdefensins arose in Old World Monkeys, after that lineage had separated from the prosimians and New World Monkeys. Although some nonhuman primates continue to produce θdefensin peptides today, Homo sapiens and his gorilla, bonobo, and chimpanzee relatives do not. Their inability to do so reflects the common inheritance of defective θdefensin genes which contain a premature stop codon that aborts translation. We can only speculate if this ancient genetic event has any contemporary relevance. However, it is noteworthy that synthetic retrocyclins can prevent the entry of HIV-1 and other viruses (e.g., HSV-2) into otherwise susceptible human target cells. Our studies suggest that their antiviral properties are intimately linked to an ability to bind carbohydrate epitopes displayed by viral and cell-surface glycoproteins involved in viral entry. The ability of retrocyclins to recognize and bind carbohydrate and glycan moieties is shared by θdefensins (RTDs) from rhesus monkeys and by several - but not all - human αdefensins. In addition to being the only cyclic peptides of animal origin, the lectin-like activity of θdefensins gives them the added distinction of being the smallest sugar-binding molecules of natural origin identified to date. This unusual combination makes θdefensins intriguing molecular prototypes that could be used to design novel carbohydrate-binding or antiviral agents.
Export Options
About this article
Cite this article as:
Cole M. Alexander, Wang Wei, Waring J. Alan and Lehrer I. Robert, Retrocyclins: Using Past as Prologue, Current Protein & Peptide Science 2004; 5 (5) . https://dx.doi.org/10.2174/1389203043379657
DOI https://dx.doi.org/10.2174/1389203043379657 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Endothelial Lipase: A Key Player in HDL Metabolism Modulates Inflammation and Atherosclerotic Risk
Mini-Reviews in Medicinal Chemistry MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists
Current Molecular Pharmacology Development on PEG-modified Poly (Amino Acid) Copolymeric Micelles for Delivery of Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Update for Cancer Therapy with β-Lapachone
Medicinal Chemistry Reviews - Online (Discontinued) Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in ApcMin/+ Mice
Current Cancer Drug Targets TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents The PAX8 / PPARγ Fusion Oncogene as a Potential Therapeutic Target in Follicular Thyroid Carcinoma
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma
Current Gene Therapy Constrained Analogs of Osteogenic Peptides
Current Medicinal Chemistry Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research